2. Cell Cycle/DNA Damage Stem Cell/Wnt
  3. Casein Kinase
  4. Ellagic acid hydrate

Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM.

For research use only. We do not sell to patients.

CAS No. : 314041-08-2

Size Price Stock Quantity
10 mg In-stock
25 mg Get quote
50 mg Get quote
100 mg Get quote
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 22 publication(s) in Google Scholar

Other Forms of Ellagic acid hydrate:

Ellagic acid hydrate Related Antibodies

Top Publications Citing Use of Products

    Ellagic acid hydrate purchased from MedChemExpress. Usage Cited in: Cell Prolif. 2025 May 19:e70064.  [Abstract]

    Representative fluorescent images showing the internalisation of Dil‐labelled EVs and EA‐sEVs by HG‐HDFs and HG‐HEKs at 6 h; scale bar, 50 μm. Blue: DAPI, red: Dil, green: Phalloidine.

    Ellagic acid hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2680-2700.

    After treatment with different concentrations of Ellagic acid (0-20 μM) for 24 h, the expression of SIRT6, SGK1, H3K9 and H3K56 in primary cardiomyocytes isolated from WT mice and LLC cells was examined by Western blotting. β-Actin was used as a loading control. Semiquantitative analyses of bands were performed using ImageJ software.

    Ellagic acid hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2680-2700.

    Primary cardiomyocytes isolated from WT mice and LLC cells were transfected with SIRT6 siRNA or control siRNA. After pre-treated with Ellagic acid (10 μmol/L) for 24 h, Dox (0.5 μmol/L) was added to culture medium for subsequent 24 h, and apoptosis was analyzed by TUNEL assays. Representative images are shown (scale bar = 100 μm). The TUNEL-positive rates were quantified blindly in 5 images from different fields.

    Ellagic acid hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2680-2700.

    Wild-type C57BL/6 mice were inoculated subcutaneously with 1.5 × 106 LLC-Luc cells (LLC cells stably expressing the luciferase gene). After tumors became visible (approximately 7 days), the tumor-bearing mice were treated with Dox (10 mg/kg/week, i.v.) or/and Ellagic acid (100 mg/kg/2 days, i.g.) for 2 weeks. Tumor volume was visualized using the IVIS Imaging System before and after treatment, and representative bioluminescence images and quantitative analyses of the tumor-bearing mice are shown.

    Ellagic acid hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2023 Jun;13(6):2680-2700.

    Wild-type C57BL/6 mice were inoculated subcutaneously with 1.5 × 106 LLC-Luc cells (LLC cells stably expressing the luciferase gene). After tumors became visible (approximately 7 days), the tumor-bearing mice were treated with Dox (10 mg/kg/week, i.v.) or/and Ellagic acid (100 mg/kg/2 days, i.g.) for 2 weeks. Cell morphology, fibrosis and apoptosis in the cardiac tissue of the tumor-bearing mice were examined by H&E, Masson and TUNEL staining, respectively. Cell morphology, proliferation and apoptosis and in the tumors were measured by H&E, Ki67 immunofluorescence and TUNEL staining, respectively.

    View All Casein Kinase Isoform Specific Products:

    View All Isoforms
    CK1 CK2

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ellagic acid hydrate is a natural antioxidant, and acts as a potent and ATP-competitive CK2 inhibitor, with an IC50 of 40 nM and a Ki of 20 nM[1].

    IC50 & Target[1]

    CK2

    20 nM (Ki)

    CK2

    40 nM (IC50)

    Clinical Trial
    Molecular Weight

    320.21

    Formula

    C14H8O9
    CAS No.
    Appearance

    Powder

    SMILES

    O=C1C2=CC(O)=C(O)C(O3)=C2C4=C(C3=O)C=C(O)C(O)=C4O1.[H]O[H]
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 3 mg/mL (9.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.1230 mL 15.6148 mL 31.2295 mL
    5 mM 0.6246 mL 3.1230 mL 6.2459 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.1230 mL 15.6148 mL 31.2295 mL 78.0738 mL
    5 mM 0.6246 mL 3.1230 mL 6.2459 mL 15.6148 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ellagic acid hydrate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ellagic acid314041-08-2Casein KinaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ellagic acid hydrate
    Cat. No.:
    HY-B0183A
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.